Bumetanide is a loop diuretic with actions and uses similar to those of furosemide. Bumetanide is used in the treatment of edema associated with heart failure and with renal and hepatic disorders. Bumetanide has also been used in hypertension. Bumetanide, a potent loop diuretic with a rapid onset and short duration of action, inhibits the reabsorption of sodium and chloride in the ascending limb of the loop of Henle and enhances the excretion of potassium in a dose-related manner. It exerts effects on the proximal tubule causing phosphate in urine, but it does not seem to possess any significant activity on the distal tubule. It also increases serum uric acid and reduces uric acid excretion.
Affygility Solutions has an occupational exposure limit (OEL) and control band assignment for this active pharmaceutical ingredient (API). This monograph also contains the acceptable daily exposure (ADE) value.
OEL Fastrac monographs are a cost-effective and convenient way to meet the requirements for PDEs (ADEs) contained in the EMA Guideline on setting health based exposure limits for use in risk identification in the manufacture of different medicinal products in shared facilities (EMA/CHMP/CVMP/SWP/169430/2012), and to obtain the following information:
To order an OEL monograph for this compound, just click the ADD TO CART button.
Not the compound you were looking for? You can search the OEL Fastrac catalog to find more available compounds.
Affygility Solutions’s OEL Fastrac service is an user-friendly system that enables us to make confident decisions and focus on moving the compound safely through our facility. We can quickly access the database to determine if a new drug is within the OEL Fastrac library, and if so, immediately download a detailed OEL banding report. The OEL Fastrac system has been a helpful tool in our overall EH&S program.